Tff Pharmaceuticals, Inc. TFFP
We take great care to ensure that the data presented and summarized in this overview for TFF Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TFFP
View allLatest Institutional Activity in TFFP
Top Purchases
Top Sells
About TFFP
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's lead drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It is also developing other dry powder products, such as cannabidiol substance for the treatment of various epilepsy syndromes, as well as anxiety, insomnia, and various pain; Inhaled SARS-CoV2 Monoclonal Antibody for the treatment of patients with COVID-19 infections; Niclosamide Inhalation Powder to treat tapeworm infections in humans, as well as COVID-19 disease; and other vaccines. The company has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop inhaled SARS-CoV2 monoclonal antibody; and a licensing and collaboration agreement with UNION therapeutics A/S. The company was incorporated in 2018 and is based in Austin, Texas.
Insider Transactions at TFFP
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Aug 16
2023
|
Carlson Capital L P > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,000
-0.02%
|
$0
$0.39 P/Share
|
Aug 15
2023
|
Carlson Capital L P > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
215,000
-4.07%
|
$0
$0.44 P/Share
|
Aug 15
2023
|
Zamaneh Mikhak Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
120,000
+47.06%
|
$0
$0.25 P/Share
|
Aug 15
2023
|
Robert S Mills Director |
BUY
Open market or private purchase
|
Direct |
40,000
+41.68%
|
$0
$0.25 P/Share
|
Aug 15
2023
|
Kirk Allen Coleman Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
20,000
+35.92%
|
$0
$0.25 P/Share
|
Aug 15
2023
|
Brandi Roberts Director |
BUY
Open market or private purchase
|
Direct |
20,000
+50.0%
|
$0
$0.25 P/Share
|
Aug 15
2023
|
Stephen Rocamboli Director |
BUY
Open market or private purchase
|
Direct |
20,000
+35.71%
|
$0
$0.25 P/Share
|
Aug 15
2023
|
Harlan F Weisman President and CEO |
BUY
Open market or private purchase
|
Direct |
600,000
+42.41%
|
$0
$0.25 P/Share
|
Mar 10
2023
|
Stephen Rocamboli Director |
BUY
Open market or private purchase
|
Direct |
13,000
+44.83%
|
$0
$0.8 P/Share
|
Mar 10
2023
|
Zamaneh Mikhak Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
15,000
+50.0%
|
$0
$0.82 P/Share
|
Mar 10
2023
|
Harlan F Weisman President and CEO |
BUY
Open market or private purchase
|
Direct |
150,000
+41.14%
|
$0
$0.88 P/Share
|
Mar 10
2023
|
Kirk Allen Coleman Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
12,000
+43.36%
|
$0
$0.79 P/Share
|
Dec 15
2022
|
Harlan F Weisman President and CEO |
BUY
Open market or private purchase
|
Direct |
50,000
+43.62%
|
$50,000
$1.06 P/Share
|
Nov 22
2022
|
Aaron G.L. Fletcher Director |
BUY
Open market or private purchase
|
Direct |
43,470
+23.25%
|
$43,470
$1.15 P/Share
|
Sep 29
2022
|
Randy H Thurman Director |
SELL
Open market or private sale
|
Direct |
40,255
-100.0%
|
$161,020
$4.29 P/Share
|
Sep 29
2022
|
Randy H Thurman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
40,255
+50.0%
|
$80,510
$2.5 P/Share
|
May 20
2022
|
Harlan F Weisman President and CEO |
BUY
Open market or private purchase
|
Direct |
4,615
+24.0%
|
$23,075
$5.5 P/Share
|
May 18
2022
|
Harlan F Weisman President and CEO |
BUY
Open market or private purchase
|
Direct |
2,500
+20.0%
|
$12,500
$5.12 P/Share
|
May 17
2022
|
Kirk Allen Coleman Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
425
+10.37%
|
$1,700
$4.83 P/Share
|
May 17
2022
|
Aaron G.L. Fletcher Director |
BUY
Open market or private purchase
|
Indirect |
24,600
+18.33%
|
$123,000
$5.08 P/Share
|
Last 12 Months Summary
Open market or private purchase | 820K shares |
---|
Open market or private sale | 216K shares |
---|